
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Operating Expenses
OSE Immunotherapeutics SA
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Operating Expenses
-€29.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
Operating Expenses
-€57.3m
|
CAGR 3-Years
36%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-3%
|
|
![]() |
Nanobiotix SA
PAR:NANO
|
Operating Expenses
-€61.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-22%
|
|
G
|
Genfit SA
PAR:GNFT
|
Operating Expenses
-€58m
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-12%
|
|
![]() |
Inventiva SA
PAR:IVA
|
Operating Expenses
-€115.7m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Operating Expenses
-€53.3m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-10%
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Operating Expenses?
Operating Expenses
-29.5m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Operating Expenses amounts to -29.5m EUR.
What is OSE Immunotherapeutics SA's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-7%
Over the last year, the Operating Expenses growth was 9%. The average annual Operating Expenses growth rates for OSE Immunotherapeutics SA have been 7% over the past three years , -7% over the past five years .